ArticleDiabetes & vascular disease research

Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus.

Sharmaine Thirunavukarasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.